Published in JAMA Network Open · View the paper (DOI)
A large number of patients received anti–SARS-CoV-2 monoclonal antibodies despite FDA deauthorization due to their limited effectiveness against the Omicron variant. This widespread use resulted in significant Medicare spending, estimated at over $71 million.
Coverage from 2 institutions